NCT02479178

A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 73 (actual)
• Sponsor: BIND Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with advanced urothelial carcinoma, cervical cancer, cholangiocarcinoma or carcinomas of the biliary tree and squamous cell carcinoma of the head and neck. Ferumoxytol imaging will also be investigated at US sites as an exploratory endpoint.

Conditions

• Urothelial Carcinoma
• Cholangiocarcinoma
• Cervical Cancer
• Squamous Cell Carcinoma of Head and Neck

Interventions

Type	Name	Description
DRUG	BIND-014 (docetaxel nanoparticles for injectable suspension)	docetaxel nanoparticles for injectable suspension

Timeline

• Start date: 2015-06-01
• Primary completion: 2016-10-01
• Completion: 2020-01-01
• First posted: 2015-06-24
• Last updated: 2016-04-14

Locations

23 sites across 2 countries: United States, Russia